Full-Time

Critical Care Business Manager

Posted on 5/9/2026

Mallinckrodt

Mallinckrodt

1,001-5,000 employees

Specialty pharmaceutical developer, manufacturer, distributor

Compensation Overview

$146k - $168k/yr

+ Bonus

Washington, DC, USA + 2 more

More locations: Alexandria, VA, USA | Bethesda, MD, USA

In Person

Some overnight travel may be required.

Category
Sales & Account Management (1)
Requirements
  • B.A. or B.S. degree in relevant field, and 2 plus years recent hospital sales experience or 5 plus years Specialty sales
  • In lieu of a Bachelor’s degree, will consider either an Associate’s Degree and 5+ years of successful, proven pharmaceutical or industry equivalent experience within hospital / Institutions
  • Current experience within the territory and customer knowledge highly preferred
  • Strong technical and clinical presentation and selling skills
  • Excellent verbal and written communication and interpersonal skills
  • Proven track record of sales success and strong business acumen
  • Excellent planning and organizational skills
  • Strong collaboration and teamwork skills
  • Valid driver’s license
  • Required to pass all product training testing
  • Overnight travel
  • Excellent computer skills
  • Preferred: B.A. or B.S. degree in relevant field, M.B.A. a plus
  • Academic and community institutional selling experience
  • Institutional contracting process experience
  • Institutional contracting process experience
  • Respiratory Therapy experience in Institution(s)
  • Ventilator sales/field experience
Responsibilities
  • Effectively communicates about the product & overcomes objections
  • Understands disease state and therapeutic area
  • Uses clinical data in selling product
  • Understands the market landscape and competing products
  • Analyzes territory and account data, uses judgment and experience to identify business opportunities
  • Prioritizes sales activities and continually evaluates targets to meet goals and track sales impact
  • Develops KOLs and implements programs consistent with product strategy to drive sales results
  • Develops and maintains relationships with internal colleagues and external HCPs/Customers
  • Ensures compliance with all applicable laws, policies and procedures in conducting business
  • Meets specific expectations on speaker events and other available resources
  • Fully Competent to train on the device to all levels of users
Desired Qualifications
  • In addition to required, be willing to travel overnight as needed
  • Local travel; some overnight required, may vary depending on the region
  • Keenova Total Rewards package details not a job requirement

Mallinckrodt is a global specialty pharmaceutical company that develops, manufactures, and distributes drugs and therapies for complex and rare conditions, serving healthcare providers, hospitals, and patients mainly in the United States and Europe. Its products target areas such as autoimmune diseases, rare diseases, and critical care, and the business rests on research and development, manufacturing, and sales. The company differentiates itself through a patient-centric approach, a commitment to integrity, ongoing innovation, and collaboration, grounded in more than 150 years of experience and a focus on ESG initiatives. Its goal is to improve the health and well-being of patients worldwide by delivering specialty medicines and advancing sustainable practices.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Hazelwood, Missouri

Founded

1867

Simplify Jobs

Simplify's Take

What believers are saying

  • Merger with Endo completed, forming NYSE-listed therapeutics leader by Q4 2025.
  • Reduced debt 47% to $865.6M and grew Acthar Gel sales 14.2% in 2024.
  • Sold Therakos for $925M, optimizing portfolio for specialty pharmaceuticals.

What critics are saying

  • Endo merger integration disrupts operations, overloading with $6.7B debt.
  • Therakos sale drops immunotherapy revenue, losing edge to Amgen immediately.
  • Acthar Gel's $300K pricing triggers DOJ probe and $500M fines within 18 months.

What makes Mallinckrodt unique

  • Mallinckrodt specializes in Acthar Gel for autoimmune diseases over 150 years.
  • Focuses on rare diseases and critical care therapies for underserved patients.
  • Launched Acthar Gel self-injectable to improve patient adherence and convenience.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Mallinckrodt who can refer or advise you

Benefits

Performance Bonus

Relocation Assistance

Company News

PR Newswire
Nov 10th, 2025
Par Health Completes Spin-Off from Mallinckrodt, Creating an Independent Leader in Generic Pharmaceuticals and Sterile Injectables

Launches as Top 15 U.S. Generic Drug Manufacturer, Largest U.S. Producer of Active Pharmaceutical Ingredients and Premier U.S. Producer of Sterile Injectables...

Contract Pharma
Aug 6th, 2025
Mallinckrodt Names Christiana Stamoulis President and CFO

Mallinckrodt plc appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025.

Stock Titan
Aug 1st, 2025
Mallinckrodt-Endo Merger Creates Therapeutics Leader

Mallinckrodt and Endo have completed a merger to form a global therapeutics leader. The companies will combine their generics businesses and Endo's sterile injectables business, which will be spun off as an independent company by Q4 2025. The newly branded company will be listed on the New York Stock Exchange following the spin-off.

The Business Journals
Jul 25th, 2025
Mallinckrodt Reaches $7B Merger Milestone

Mallinckrodt has reached a milestone in a $7 billion merger deal.

Sharecast
Mar 13th, 2025
Mallinckrodt and Endo to merge in $6.7bn deal

Pharmaceutical firm Mallinckrodt said on Thursday that it has agreed to merge with Endo in a $6.7bn deal.